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ABSTRACT
Lamin A/C gene mutations can be associated with cardiac diseases, usually referred to as ‘cardiolami-
nopathies’ characterized by arrhythmic disorders and/or left ventricular or biventricular dysfunction up
to an overt picture of heart failure. The phenotypic cardiac manifestations of laminopathies are fre-
quently mixed in complex clinical patterns and specifically may include bradyarrhythmias (sinus node
disease or atrioventricular blocks), atrial arrhythmias (atrial fibrillation, atrial flutter, atrial standstill),
ventricular tachyarrhythmias and heart failure of variable degrees of severity. Family history, physical
examination, laboratory findings (specifically serumcreatinephosphokinase values) andECG findings are
often important ‘red flags’ in diagnosing a ‘cardiolaminopathy’. Sudden arrhythmic death, thromboem-
bolic events or stroke and severe heart failure requiring heart transplantation are the most dramatic
complications of the evolution of cardiolaminopathies and appropriate risk stratification is clinically
needed combined with clinical follow-up. Treatment with cardiac electrical implantable devices is
indicated in case of bradyarrhythmias (implant of a device with pacemaker functions), risk of life-
threatening ventricular tachyarrhythmias (implant of an ICD) or in case of heart failure with wide QRS
interval (implant of a device for cardiac resynchronization). New technologies introduced in the last
5 years can help physicians to reduce device-related complications, thanks to the extension of device
longevity and availability of leadless pacemakers or defibrillators, to be implanted in appropriately
selected patients. An improved knowledge of the complex pathophysiological pathways involved in
cardiolaminopathies and in the determinants of their progression to more severe forms will help to
improve clinical management and to better target pharmacological and non-pharmacological
treatments.
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Laminopathies and the heart
Lamins A and C are intermediate filament nuclear
envelope proteins supporting the structure and func-
tion of the nucleus of eukaryotic cells and are encoded
by the LMNA gene [1–3].
Lamin A/C gene mutations can be associated with
cardiac diseases, usually referred to as ‘cardiolamino-
pathies’ characterized by arrhythmic disorders and/or
left ventricular or biventricular dysfunction up to an
overt picture of heart failure.
The first report stressing the importance of lamin
A/C mutations as the genetic basis for important
cardiac consequences in terms of dilated cardiomyo-
pathy and arrhythmic events was the study by Bonne
et al. on Emery-Dreifuss muscular dystrophy [1].
In Emery-Dreifuss muscular dystrophy [1], car-
diac abnormalities, leading to life-threatening bra-
dyarrhythmias either of sinus and atrial origin
(sino-atrial blocks, atrial standstill) or atrioventri-
cular blocks (up to third degree atrioventricular
block), ventricular tachyarrhythmias, sudden
death and dilated cardiomyopathy with heart fail-
ure of variable degree are not strictly correlated
with the severity of the neuromuscular disease
affecting the skeletal muscles [4]. Figure 1 shows
the phenotypic cardiac manifestations of lamino-
pathies, which are frequently mixed in complex
clinical patterns. Family history, physical examina-
tion, laboratory findings (specifically serum crea-
tine phosphokinase values) and ECG findings are
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often important ‘red flags’ in diagnosing a
‘cardiolaminopathy’.
Laminopathies involve a wide spectrum of dis-
eases affecting striated muscle, the heart, the adi-
pose tissue, and peripheral nerves or can be a
multi-organ and multi-system disease as in the
Hutchinson-Gilford progeria syndrome [3,5] and
cardiac disturbances may be present in patients
with quite different phenotypes due to lamin A/C
mutations.
Phenotypic penetrance is age-related but the
expression is extremely heterogeneous, so that mus-
cular and arrhythmic disease can be present in com-
bination in the same patient, or one phenotypic
manifestation can appear earlier than the other or
even not become overt for a long time [6].
Moreover, both the severity of the disease and its
progression may have a marked interindividual varia-
bility also within the same family of affected patients.
From a cardiological point of view, characteri-
zation of a patient as affected by a laminopathy
with heart involvement (‘cardiolaminopathy’) is of
crucial importance, since clinical and prognostic
implications, as well as specific management stra-
tegies, can be different, particularly with regard to
prevention of sudden cardiac death. A specific
diagnosis, based on genetic testing, and appropri-
ate risk stratification with referral to expert centers
involving a multidisciplinary team for appropriate
decision-making is currently needed in patients
affected by the various manifestations of this
disease.
Pathogenetic pathways in
cardiolaminopathies
The pathophysiology of cardiolaminopathies is
complex, as summarized in Figure 2.
Two main pathogenetic pathways have been iden-
tified as the basis of cardiolaminopathies.
The first and better described pathway starts
from activation of Erk 1/2 signaling leading to a
profibrotic process, which encompasses TGFbeta
2-dependent activation of connective tissue growth
factor [7,8]. The pathogenicity of Erk 1/2 activa-
tion has been proven in preclinical models.
Inhibitors of Erk 1/2 or MEK or other molecules
in the signaling pathway have been able to delay
the onset of cardiomyopathy in LmnaH222P/H222P
mice, which die prematurely due to cardiac
impairment [9]. Further, activation of PI3-kinase
leading to Akt/mTOR phosphorylation, has been
demonstrated in laminopathic mice. The event
downstream of mTOR activation was inhibition
of autophagic detoxification in cells, a deleterious
effect that could be counteracted in vivo by rapa-
mycin or its analogs, mTOR inhibitors used in
several clinical applications [10,11].
However, at least one additional pathomechanism
is expected to play a role in laminopathic heart.
Lamins are major sensors at the nuclear envelope
and respond to bothmechanical and chemical stimuli.
The connectionwith extranuclear signal transducers is
ensured by the Linker of Nucleoskeleton and
Cytoskeleton (LINC) complex, a protein chain includ-
ing integral proteins of the inner and outer nuclear
membrane, such as SUN1/2 and nesprin1/2 (encoded
by SYNE1/2 genes), attached to lamins on the nuclear
side and to actin and other cytoskeleton constituents
on the cytoplasmic side. LINC proteins are reduced
[12,13] or evenmutated [13,14] in patients affected by
cardiolaminopathies. The proven effect of LINC dis-
organization and reduced interplay between LINC
components and lamins in laminopathic muscle cells
is defectivemyonuclear positioning [12,14], which is a
cause of altered muscle cell functionality [14]. These
findings point to altered mechanosignalling transduc-
tion as a further pathogenetic event leading to heart
Figure 1. Spectrum of cardiac involvement in cardiolaminopa-
thies, with regard to arrhythmic disturbances and heart failure.
Legend: AV: atrio-ventricular, LV: left ventricular.
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dysfunction in laminopathies. Mechanosignalling is
particularly relevant in conduction tissue, which
deserves better investigation. In this respect, it is
worth mentioning that reduced connexin 43 amount
at the intercalated disks and altered disk morphology
are linked to defects in Wnt/betaCatenin signaling in
laminopathic heart [8].
These pathogenetic pathways are not mutually
exclusive; instead they could be recapitulated in a
unique mechanism that, starting from failure of
mutated lamin A to regulate TGFbeta 2 levels [15],
implies TGFbeta 2 increase [16] and TGFbeta2-
dependent activation of Erk 1/2 and mTOR leading
to fibrosis [7,15] and loss of autophagic detoxification
[11]. In this context, elevated TGFbeta 2 and Akt/
mTOR activation could also be the cause of reduced
lamin A and prelamin A levels [15,17] at the cardio-
myocyte nuclear envelope, a condition that favors
LINC disorganization [12]. In agreement with this
pathogenetic hypothesis, Erk 1/2 activation has been
demonstrated in the presence of pathogenetic LMNA
and SYNE1 mutations [7,13], and altered positioning
of muscle nuclei has been demonstrated in LMNA,
SYNE1 and SUN1-linked Emery-Dreifuss muscular
dystrophy with cardiomyopathy [12–14,18].
Further studies will better define the complex
molecular mechanism leading to cardiolaminopathies
and confirm Erk ½ [9], mTOR [11], TGFbeta 2 [16]
betaCatenin [8] or connective tissue growth factor [7]
as targets of therapeutic intervention.
Genotype-phenotype correlations
A series of studies have shown that there are no clear
genotype-phenotype correlations, as different muta-
tions in the same codon, or even the same mutation,
may produce a variety of clinical symptoms [2,3]. This
means that, despite common pathogenic pathways,
the severity of the disease and the prevalent skeletal
or cardiac muscle involvement might be regulated by
modifying genes, as demonstrated in a family harbor-
ing LMNA and TTN mutations [18] or in families
with LMNA and desmin gene mutations [19,20].
Cardiac manifestations of laminopathies and
clinical decision-making
The most common clinical manifestations are dizzi-
ness, syncope, palpitations, or even ischemic stroke
due to cardioembolism (in the case of atrial fibrillation
or atrial standstill) but also ventricular tachyarrhyth-
mias and sudden death and/or worsening heart failure
may occur, the latter usually at a later stage in the
course of the disease [4,21–24]. We will describe the
clinical characteristics of these symptoms, focusing on
the need for a disease-oriented decision-making. As a
matter of fact, the tendency of the disease to progress
to more advanced stages with risk of life-threatening
events, makes it necessary to interpret clinical findings
and take appropriate decisions in the presence of
clinical elements that in the context of this disease
Figure 2. Main pathogenetic pathways in the pathophysiology of cardiolaminopathies.
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have a special relevance, differently from the signifi-
cance that the same findings may have in the absence
of a cardiolaminopathy.
Implantation of a pacemaker has been traditionally
proposed for protecting against the consequences of
bradyarrhythmias, but consideration for an implanta-
ble cardioverter defibrillator (ICD), able to interrupt
malignant ventricular tachyarrhythmias, thus pre-
venting sudden cardiac death, may become a priority
inmany patients who have the indication to implant a
cardiac electrical device. Biventricular pacing is a form
of cardiac stimulation, referred to as cardiac resyn-
chronization therapy (CRT), that may improve car-
diac function in the case of heart failure, low ejection
fraction and ventricular dyssynchrony [25].
Bradyarrhythmias, atrial fibrillation and atrial
flutter
Bradyarrhythmias and supraventricular tachyar-
rhythmias are common features in laminopathies
and often anticipate by decades the development
of heart failure due to dilated cardiomyopathy
[4,24]. Supraventricular arrhythmias include atrial
flutter, atrial fibrillation, and atrial tachycardia,
and may be associated with sinus node dysfunc-
tion (i.e. tachycardia-bradycardia syndrome).
Atrial bradycardia at a young age (early second
decade to fourth decade), followed by evolution
to atrial standstill and with associated high-grade
atrioventricular block or complete atrio-ventricu-
lar block are typical features of X-linked Emery-
Dreifuss muscular dystrophy and pacemaker
implant may be necessary even on an emergency
basis, for syncope or low cardiac output, at an age
around 20 [4], Table 1 shows the results of a
complete review of the literature, with data on
the specific arrhythmic profile of patients with
various forms of laminopathies, according to
genetic characterization.
Low amplitude P wave, prolonged PR interval,
left anterior hemiblock, and bundle branch block
are typical features at the electrocardiogram of
involvement of the conduction system and repre-
sent ‘red flags’ for the diagnosis of a cardiolamino-
pathy at a relatively young age.
In general, considering the high risk of bradyar-
rhythmias, the threshold for cardiac pacing through
a device should be low and in the presence of atrio-
ventricular conduction abnormalities or sinus node
dysfunction disease-specific decision-making is
recommended, in view of the natural history of
the disease. In specific cases, the assessment of
infra-hisian conduction at an electrophysiologic
study (pathologic if measured HV interval is
>70 ms) may help in decision-making with regard
to the indication for permanent cardiac pacing.
Figure 3 shows an example of typical echocar-
diographic and electrocardiographic findings in a
patient with cardiolaminopathy, who was in sinus
rhythm, but with episodes of paroxysmal atrial
fibrillation and presented an atrial thrombus in
the left atrial appendage at transesophageal
echocardiogram.
In the general population atrial fibrillation is
usually an arrhythmia characteristic of the elderly
[26], while it is rare at an age <30 and its onset at a
young age should therefore raise the suspicion of a
genetic cause and specifically of a laminopathy.
Atrial fibrillation has been reported in around
60% of patients with a cardiolaminopathy [4,27],
often with atrial fibrillation occurring at a young
age (12–20 years) as the first cardiac manifestation
of the disease, with or without neuromuscular
symptoms [4]. In patients with cardiolaminopathy
with the pattern of a dilated cardiomyopathy, the
prevalence of atrial fibrillation is higher than 90%
[27]. In the series reported by Olilla et al [27].,
atrial fibrillation had a higher incidence in males
as compared to female patients and men presented
with atrial fibrillation at an earlier age (41 vs
54 years, p = 0.016).
The evolution of the pathologic processes at the
atrial level is progressive and in a histopathologic
post-mortem study on three hearts a marked loss
of atrial myocardium was found, with evidence
that the atrial myocardium had been replaced by
adipose and fibrous tissue [28]. This impressive
derangement of the atrial walls fits with the recent
concepts of ‘atrial cardiomyopathy’[29], corre-
sponding to any complex of structural, architec-
tural, contractile or electrophysiological changes
affecting the atria with the potential to produce
clinically-relevant manifestations [30]. The extent
and the progression of atrial structure derange-
ment in cardiolaminopathies are the basis for the
progression of clinical arrhythmias, with atrial
fibrillation and flutter (which require some
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amount of excitable atrial tissue) typically followed
over time by atrial standstill, as an expression of an
extensive loss of viable atrial tissue [4].
The clinical implications of the pathological
progression described at the atrial level is that
catheter ablation procedures targeted to maintain
sinus rhythm in patients presenting with atrial
fibrillation, as well as repeated electrical cardiover-
sions, have no chance of being successful at mid
and long-term. Moreover, attempts to stimulate
the atria by a dual-chamber pacemaker regularly
fail due to progressive development of atrial stand-
still and atrial inexcitability by electrical stimuli,
even if delivered at high electrical output [4].
Thromboembolic complications and cardio-
embolic stroke
Patients with laminopathies have a high risk of
stroke due to cardioembolism, and this event,
often disabling, has been reported to occur in up
to 33–36% of cases in series of patients with car-
diolaminopathies presenting atrial fibrillation in
56–61% of cases [4,27], (Table 1). In one series,
ischemic stroke due to cardioembolism occurred
in 36% of patients with atrial fibrillation (all not
treated with oral anticoagulants), in half of the
case aged <45, and resulted in significant
disability.
It is well known that in patients with atrial
fibrillation the risk of thromboembolism can be
predicted by the CHA2DS2-VASc score, but this
score has been validated in clinical contexts and
patient ages completely different from laminopa-
thies [31]. The association between cardiolamino-
pathies and a high risk of cardioembolic stroke
even at a young age and with low CHA2DS2-
VASc scores indicates that the conventional risk
stratification adopted for atrial fibrillation patients
cannot be translated to this specific setting as a
guide to anticoagulation and that the high risk of
cardioembolic stroke, dependent on many interre-
lated factors (Figure 4), suggests starting oral
anticoagulation, in the absence of absolute contra-
indications, in any patient with a cardiolaminopa-
thy and with documented atrial fibrillation or with
other atrial tachyarrhythmias (atrial flutter, atrial
tachycardia) or with atrial paralysis. Despite the
absence of controlled trials, the high occurrence of
ischemic stroke at young age in untreated patients
Figure 3. Echocardiographic (top) and electrocardiographic (bottom) findings of a typical cardiolaminopathy with paroxysmal atrial
fibrillation. Panel A. Four-chamber view transthoracic echocardiography showing severe dilatation of both atria and severe dilatation
and hypokinesia of both ventricles (ejection fraction of both left and right ventricles 20%). Panel B. Transesophageal echocardio-
graphy 60 degree view showing a trombus inside the left atrial appendage. Panel C. Electocardiogram: sinus rhythm, atrio-ventricular
first degree A-V block, left anterior hemiblock and ventricular repolarization abnormalities.
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suggests this disease-specific recommendation
[4,27]. The current availability of non-vitamin K
antagonist anticoagulants for so-called non-valvu-
lar atrial fibrillation [32], that do not require per-
iodic monitoring of the level of anticoagulation,
greatly facilitates the initiation of this antithrom-
boembolic prophylaxis [33–35].
Atrial fibrillation may be asymptomatic or asso-
ciated with atypical symptoms in 30–40% of unse-
lected patients [36], and the implications for
outcome are poor, since the risks of cardiovascular
death, all-cause death and stroke are higher in
patients with asymptomatic versus symptomatic
atrial fibrillation [37,38]. No specific data are avail-
able on the ratio of asymptomatic versus sympto-
matic atrial fibrillation in cardiolaminopathies, but
the frequent association with alterations of atrio-
ventricular conduction, limiting the occurrence of
fast ventricular rates, makes the chance of asymp-
tomatic atrial fibrillation even higher than in the
general population. In view of the risk of stroke
and thromboembolism related to atrial fibrillation,
regardless of the presence/absence of symptoms
like palpitations, periodic checks with a 12-lead
electrocardiogram are indicated in patients with
known cardiolaminopathy or in lamin A/C muta-
tion carriers. The role of opportunistic or systema-
tic screening, using hand-held devices for single-
lead electrocardiogram or ECG event monitors or
using more recent user-friendly tools, such as
smartphones or bracelets with dedicated software,
has still to be assessed in this specific context
[39,40] but may be of great value in view of the
relatively high pre-test probability of developing
atrial tachyarrhythmias. Similarly, the diagnostic
capabilities of implanted devices for bradyarrhyth-
mias and prevention of sudden cardiac death (i.e.
pacemakers and defibrillators) can help in detect-
ing atrial fibrillation through their diagnostic cap-
abilities, even if the implant of devices without an
atrial lead limits the diagnostic accuracy unless
dedicated algorithms are implemented [41] .
In a study comparing lamin A/C mutation car-
riers [42] (atrial tachyarrhythmias in 63% and
depressed systolic function in 46% of cases) with
patients with dilated cardiomyopathy not due to
lamin A/C mutations, the prevalence of throm-
boembolic complications (more commonly arter-
ial, but also venous) was higher during follow up
in the cohort of lamin A/C mutation carriers and
after adjustment for possible confounders, includ-
ing atrial tachyarrhythmias and left ventricular
ejection fraction, lamin A/C mutation carriership
was independently associated with an increased
risk of thromboembolic complications (HR 4.8,
95% CI: 2.2–10.6). The same study [42] found a
higher thrombin generation in lamin A/C carriers
and an altered platelet function suggesting an asso-
ciated prothrombotic state that may explain the
previous findings, as well as the observations of
van Tintelen et al. [43] of a high risk of throm-
boembolism in specific families, regardless of
Figure 4. Factors affecting the risk of thromboembolism and stroke in cardiolaminopathies and Emery-Dreifuss muscular dystrophy.
Legend: EDMD: Emery-Dreifuss muscular dystrophy.
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identifiable risk factors for thromboembolism and
of atrial tachyarrhythmias. Further research is
needed in this field.
As shown in Figure 3, other factors, such as the
use of VVI pacemakers and the frequent presence
of left ventricular non-compaction [44], may be
additional aspects increasing the risk of throm-
boembolism and stroke.
Dilated cardiomyopathy
The phenotype of dilated cardiomyopathy, charac-
terized by left ventricular or biventricular dilata-
tion, reduced systolic function and progressive
heart failure, is, in general, genetically heteroge-
neous, dependant on genes encoding cytoskeletal,
sarcomeric, mitochondrial, desmosomal, nuclear
membrane, and RNA-binding proteins [45].
Lamin A/C mutations are found in around 5% of
patients with non-familial idiopathic dilated cardi-
omyopathy, in 5%–10% of patients with idiopathic
familial dilated cardiomyopathy and in 33% of
cases of familial dilated cardiomyopathy with con-
duction defects [3,45].
From the clinical point of view, the pattern of
dilated cardiomyopathy related to the LMNA gene
does not present unique characteristics able to
clearly differentiate it from dilated cardiomyopa-
thy related to other genes or dilated cardiomyo-
pathy of non-genetic origin, although the finding
of muscular involvement (even if CPK is elevated
in only one third of cases), atrio-ventricular blocks
and atrial fibrillation or atrial flutter are consid-
ered as ‘red flags’ predicting a much higher chance
of a lamin A/C mutation [46–48]. In Table 1 data
from literature on dilated cardiomyopathies and
heart failure in reported series of patients with
cardiolaminopathies are reported. Left ventricular
dilatation may be of variable degree, also with the
pattern of ‘mildly dilated cardiomyopathy’ and can
usually be detected by two-dimensional echocar-
diography and/or with cardiac magnetic resonance
imaging (MRI). The systolic function, as measured
by left ventricular ejection fraction, has to be mea-
sured (values below 50% characterize systolic dys-
function) and monitored over time in order to
assess disease progression. The expression of the
pattern of dilated cardiomyopathy was found to be
age-dependent, with development of the
phenotype between 20 and 39 years in two thirds
of the cases and complete penetrance by
60 years [6].
Patients can be diagnosed as being affected by a
dilated cardiomyopathy as the expression of a car-
diolaminopathy following a cardiological workup
performed for symptoms of heart failure or for
arrhythmic events or can be diagnosed incidentally
or during family screening. Usually, the expression
of a pattern of dilated cardiomyopathy follows that
of the arrhythmic manifestations, or the two man-
ifestations can be associated at the time of the first
diagnosis [6]. Dilated cardiomyopathy related to
laminopathies can present an aggressive and rapid
evolution to very severe and potentially life-threa-
tening conditions, with a worse natural history in
comparison with other forms of non-ischemic
dilated cardiomyopathy [6,21]. In these cases of
progressive and worsening heart failure, other
options in addition to pharmacological treatment
can be considered. Appropriately selected patients
may benefit from cardiac resynchronization ther-
apy and even heart transplantation or mechanical
circulatory support may be needed in selected
patients [3].
Patients with cardiolaminopathy with the phe-
notype of dilated cardiomyopathy often present
left ventricular non-compaction, i.e. excessive left
ventricular trabeculae, deep intratrabecular
recesses, and a thin compacted myocardial layer
[44]. This finding, detectable at 2-dimensional
echocardiography or magnetic resonance imaging
is not unique to cardiolaminopathies, but lamin A/
C mutations are among the most frequent genetic
abnormalities detectable in patients with non-
compacted myocardium [44].
In an observational study of 94 patients with
dilated cardiomyopathy due to lamin A/C muta-
tions, the outcome in years was predicted at multi-
variable analysis by a series of variables, with New
York Heart Association functional class III to IV
and history of highly dynamic competitive sports
for ≥10 years being independent predictors of total
events (arrhythmias, heart failure, death) and
splice site mutations and competitive sport being
associated with increased risk of sudden cardiac
death [6].
In the series of cases recently reported by
Kumar et al [24] during a median follow up of
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7 years, 24% of patients without left ventricular
dysfunction at baseline developed new left ventri-
cular dysfunction and 7% developed end-stage
heart failure. Left ventricular dysfunction (ejection
fraction <50%) was associated with end-stage heart
failure or death, but the mode of presentation
(with isolated or combination of clinical features)
did not predict end-stage heart failure or death.
Cardiac resynchronisation therapy (CRT) is an
electrical therapy for heart failure that can be
applied in cases with electrical dyssynchrony (bun-
dle branch block or wide QRS at the ECG) and has
been shown to improve left ventricular systolic
performance, morbidity and mortality in patients
with heart failure [49,50]. The beneficial effects of
CRT on LV reverse remodeling and systolic func-
tion are very clear in dilated cardiomyopathy with
LV non compaction, a setting where a high pro-
portion of patients may exhibit a so called ‘super-
response’, with the evidence that the greater the
area of noncompaction (higher number of non-
compacted segments) the greater the chance of
achieving a favourable CRT response and greater
LV reverse remodeling [25].
Ventricular tachyarrhythmias and sudden
cardiac death
Sudden cardiac death due to ventricular tachyar-
rhythmias constitutes the most dramatic and
devastating event that may occur in cardiolamino-
pathies. Sudden cardiac death can be the first
manifestation of the disorder or may occur during
the course of the disease.
A detailed review of all the literature published
on the risk of ventricular tachyarrhythmias, and
on device activations in carriers of an implantable
cardioverter defibrillators (ICDs) are shown in
Table 2, in relationship to the series of patients
with laminopathies reported in Table 1
[4,6,23,24,27,43,44,47,51–62]. In the largest obser-
vational study, reported by Kumar et al [24], the
cumulative occurrence of sustained ventricular
tachyarrhythmias was 34% at 7 years, and among
patients with no history of ventricular tachyar-
rhythmias the incidence was 22% during a 7-year
follow-up. In the same series, appropriate ICD
activations occurred in 50% of patients with an
ICD implanted for primary prevention of sudden
cardiac death, with a rate of appropriate interven-
tions (3% to 7%/year) comparable to appropriate
ICD interventions occurring in high-risk patients
with idiopathic or post-infarction dilated cardio-
myopathy. In this series of patients, who were
implanted with a defibrillator in 59% of cases,
male sex, non-missense mutations, and left ventri-
cular dysfunction were associated with develop-
ment of sustained ventricular tachyarrhythmias,
while no relationship was found with the mode
of presentation (with isolated or combination of
clinical features) [24]. These findings are in line
with a previous multicentre study, where a series
of risk factors emerged as predictors of the occur-
rence of ventricular tachyarrhythmias (male gen-
der, non- sustained ventricular tachycardia, left
ventricular ejection fraction <45% and non-mis-
sense mutation), thus providing an important clin-
ical guide for the decision to implant an ICD [53]
(Table 2) [4,6,23,24,27,43,44,47,51–62]
Remote monitoring
Thanks to technological improvement, data on
electrical device parameters can be remotely trans-
mitted and this may make it possible to avoid
conventional in-hospital device checks. However,
the added value of this technology is the possibility
to monitor the patient’s clinical status and to take
appropriate clinical decisions on the basis of
detected events (e.g. new arrhythmias) or signs of
worsening clinical conditions, specifically worsen-
ing heart failure. Figure 5 shows the flow of infor-
mation in a remote monitoring system of patients
with an implanted device and transmission of
device-detected events to physicians and nurses
for appropriate decision-making. The evolving
capabilities of implanted devices to monitor the
patient’s status may imply a shift from device-
centered follow-up to patient-centered follow-up
[63]. In fact, telecardiology and remote control
make it possible not only to evaluate the device
parameters but also to detect arrhythmias and
signs of worsening heart failure with a potentially
important impact on clinical and economical out-
comes [64]. In a group of patients with neuromus-
cular disorders and with a high risk of clinical
events, remote monitoring could represent an
important clinical opportunity, whose advantages
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are in addition to avoidance of the inconvenience
of in-hospital checks, particularly tiresome in
patients with neuromuscular involvement condi-
tioning functional impairment.
Several trials demonstrated that remote control is
safe and reduces delay in detection of events such as
atrial fibrillation and worsening heart failure
[63,65,66]. The MORE CARE randomized trial
revealed a median 27-day reduction in delay from
actionable event detection to medical decision in the
device group with remote control compared to a
control group without remote data transmission
[63]. The IN-TIME randomized trial recently demon-
strated that automatic, daily, multiparameter telemo-
nitoring is associated with improved clinical outcome
for patients with heart failure, with a significant
reduction in all-causemortality [67]. This observation
requires confirmation in additional controlled trials.
The future of electrical therapies in
laminopathies
New technologies introduced in the last 5 years
can help physicians to reduce device-related com-
plications. An important innovation is the
extension of device longevity to up to 10 years.
through improvement of device batteries [68,69]
This makes it possible to reduce the number of
device replacements with benefits related to
reduced risk of infections and reduced long-term
costs [69].
Despite great technical advances over the last
decades, device implants that include transvenous
leads are still associated with some risk of compli-
cations ascribed to the damage that mechanical
stress can induce in the leads (lead fracture, lead
erosion). A leadless pacemaker is now available for
treating bradyarrhythmias, thus avoiding the risk
of lead-related complications. While such risks are
statistically rare, they represent an economic bur-
den to hospitals and the healthcare system because
of the large number of pacemaker patients (over 4
million worldwide). In the Follow Pace study, the
rate of complications was 5.5% in the 6-year follow
up of an unselected population of pacemaker
patients [70]. These data are confirmed by the
Danish registry that reported a complication rate
of 7% in around 6000 patients with a pacemaker
[71]. The rates of the specific types of device
complications are: lead-related in 2–5%, pocket-
Figure 5. Remote monitoring of patients with an implanted device: the flow of information is characterized by transmission to
physicians and nurses for appropriate decision-making on actionable clinical events.
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related in 1–4%, infection-related in 1–2% and
pneumothorax in 1–2% [70,71]. The option of
leadless pacemakers may minimize the risk of
these complications. At present, only single cham-
ber pacemakers are available, but this could repre-
sent a suitable option for patients with atrial
fibrillation or atrial standstill and neuromuscular
disorder. The early experience with a leadless
pacemaker reported a 99% implant success rate,
with 96% of patients free from major complication
[72]. In a comparison between historical controls
and leadless pacing implants, the relative risk of
major complications was reduced by 48% with the
leadless technology [73]. The data of the ‘real
world’ MICRA leadless pacemaker have recently
confirmed the short-term reliability of this type of
device implant [74,75]. The major drawback of
this technology is the limitation of single-chamber
pacing, as well as the high cost. The single cham-
ber pacemaker is a device that can be proposed for
15–20% % of patients with bradyarrhythmias
[72,74]. In patients with neuromuscular disorder
(such as Emery-Dreifuss muscular dystrophy) with
atrial fibrillation or atrial standstill, who do not
present indications for a defibrillator, implant of a
leadless pacemaker could represent an emerging
option in appropriately selected cases. In the
future the possibility to combine a leadless pace-
maker with a subcutaneous ICD may allow to
upgrade device therapy in case of evolution of
the disease, with left ventricular dysfunction devel-
oping during follow up and suggesting over time
the need for defibrillation back-up, while avoiding
intravascular leads.
As reported before, cardiac resynchronization
therapy, which is an effective treatment for heart
failure patients with left ventricular dysfunction
and wide QRS at the ECG [46], is based on
biventricular pacing, and in patients with sinus
rhythm requires an atrial lead, a right ventricular
lead and a left ventricular lead, thus increasing
the risk of lead complications over time. An
innovative system for cardiac resynchronization
therapy has been developed, including left ven-
tricular leadless pacing through a wireless, ultra-
sound-based system and 2 subcutaneous
components (battery and transmitter) in con-
junction with a co-implanted right ventricular
pacing system (Figure 6 panel D). This system
is costly and is currently proposed for patients
with a failed or ineffective conventional transve-
nous resynchronization implant, a setting includ-
ing around 15% of candidates for cardiac
resynchronization therapy. The advantage of
this kind of leadless pacemaker is that a complete
endothelization of the leadless pacemaker was
documented 3 weeks after the implant. In a pre-
liminary study, the implant success rate was high
(97%) but the rate of complications was 8.6%,
thus placing this alternative only as second or
third (after the surgical approach) option. A spe-
cific advantage of left ventricular endocardial
pacing is the opportunity to pace the ventricular
target site without phrenic nerve stimulation,
usually with very good pacing threshold.
The subcutaneous ICD is a new effective ther-
apy for ventricular tachyarrhythmia. Data show
that there are no differences in overall complica-
tions between subcutaneous and transvenous ICD
but the complications of subcutaneous ICDs can
be resolved easier [76]. The rate of lead complica-
tions is lower in subcutaneous ICDs, but non-lead-
related complication are more common.
Infections, erosions, defibrillation failure and inap-
propriate shocks have been reported to occur more
frequently in subcutaneous ICDs [76]. A recent
metanalysis confirmed these data [77], with the
exception of inappropriate shocks due to T wave
oversensing which were observed more frequently
in patients with a subcutaneous ICD as compared
to transvenous ICDs [77]. A new algorithm is
available in subcutaneous ICDs for reducing T
wave oversensing. Subcutaneous ICDs are cur-
rently not able to pace the ventricles and therefore
cannot be used in case of bradyarrhythmias. The
surgical procedure is a little more complex than a
conventional transvenous implant. Therefore, in
the specific setting of cardiolaminopathies implant
of a subcutaneous ICD can be taken into consid-
eration only when there is no indication for CRT
[78], significant bradyarrhythmias have been
excluded, and the avoidance of intravascular
leads is a clinical priority (e.g. previous device
system infection).
Figure 6 illustrates cases of clinical use of dif-
ferent types of new devices for electrical therapies
of the heart that are already available for appro-
priately and carefully selected patients.
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Conclusions
Lamin A/C gene mutations can be associated with
myocardial diseases, usually referred to as ‘cardiola-
minopathies’ characterized by arrhythmic disorders
and/or left ventricular or biventricular dysfunction
up to an overt picture of heart failure. The phenotypic
cardiacmanifestations of laminopathies are frequently
mixed in complex clinical patterns and specifically
may include bradyarrhythmias (sinus node disease
or atrioventricular blocks), atrial arrhythmias (atrial
fibrillation, atrial flutter, atrial standstill), ventricular
tachyarrhythmias and heart failure of variable degrees
of severity. Family history, physical examination,
laboratory findings (specifically serum creatine phos-
phokinase values) and ECG findings are often impor-
tant ‘red flags’ in diagnosing a ‘cardiolaminopathy’.
Sudden arrhythmic death, thromboembolic events or
stroke and severe heart failure requiring heart trans-
plantation are the most dramatic complications of the
evolution of cardiolaminopathies and appropriate risk
stratification is clinically needed, combined with clin-
ical follow-up.
Treatment with cardiac electrical implantable
devices is indicated in case of bradyarrhythmias
(implant of a device with pacemaker functions),
risk of life-threatening ventricular tachyarrhyth-
mias (implant of an ICD) or in case of heart failure
with wide QRS interval (implant of a device for
cardiac resynchronization).
New technologies introduced in the last 5 years can
help physicians to reduce device-related complica-
tions, thanks to the extension of device longevity and
availability of leadless pacemakers or defibrillators, to
be implanted in appropriately selected patients, after
careful and personalized considerations. The indica-
tions to implant a specific type of device (a pacemaker,
an ICD or a device for CRT) has to consider the
current status of the disease, its potential progres-
sion/evolution with the associated risk of developing
heart failure and/or life-threatening ventricular
arrhythmias, as well as the risk of implant-related
complications. In a multiform spectrum of diseases,
such as cardiolaminopathies, with variable phenotypic
expressions and with a potential evolution to most
Figure 6. Chest X rays showing different types of implanted electrical devices that can be considered as current therapeutic options,
according to the indications of consensus guidelines. A: transvenous cardioverter-defibrillator for prevention of sudden arrhythmic
death; B: leadless VVI pacemaker; C: subcutaneous implantable cardioverter defibrillator; D: leadless ultrasound-based left ventricular
pacing for cardiac resynchronization therapy in combination with a conventional pacemaker positioned in the right infraclavicular
region.
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severe stages that remains of difficult prediction in
individual cases, the process of clinical decision-mak-
ing with selection of a specific type implantable elec-
tronic devices has many gray zones and is not deeply
developed in the recommendations of consensus
guidelines for device implant, which are typically
referred to single diseases (atrial fibrillation, heart fail-
ure, etc.) with minimal reference to the complex pat-
tern of cardiolaminopathies. A personalization of
decision making is absolutely needed in patients with
cardiolaminopathies, taking into account discussion
of specific cases in a multidisciplinary team. The phy-
sician-patient interaction is also of primary impor-
tance, with involvement of relatives when
appropriate, and a detailed description of the specifi-
cities of implanted devices is needed for full accep-
tance of this type of therapy.
An improved knowledge of the complex patho-
physiological pathways involved in cardiolamino-
pathies and in the determinants of their
progression to more severe forms will help to
improve clinical management and to better target
pharmacological and non-pharmacological
treatments.
Disclosure statement
G. Boriani reported speaker fees of small amount from
Biotronik, Boston Scientific and Medtronic.
References
[1] Bonne G, Di Barletta MR, Varnous S, et al. Mutations
in the gene encoding lamin A/C cause autosomal
dominant Emery-Dreifuss muscular dystrophy. Nat
Genet. 1999;21:285–288.
[2] Cattin ME, Bertrand AT, Schlossarek S, et al.
Heterozygous lmnadelK32 mice develop dilated cardi-
omyopathy through a combined pathomechanism of
haploinsufficiency and peptide toxicity. Hum Mol
Genet. 2013;22:3152–3164.
[3] Captur G, Arbustini E, Bonne G, et al. Lamin and the
heart. Heart. 2018;104(6):468–479.
[4] Boriani G, Gallina M, Merlini L, et al. Clinical relevance of
atrial fibrillation/flutter, stroke, pacemaker implant, and
heart failure in Emery-Dreifuss muscular dystrophy: a
long-term longitudinal study. Stroke. 2003;34:901–908.
[5] Brayson D, Shanahan CM. Current insights into
LMNA cardiomyopathies: existing models and missing
LINCs. Nucleus. 2017;8:17–33.
[6] Pasotti M, Klersy C, Pilotto A, et al. Long-term out-
come and risk stratification in dilated cardiolaminopa-
thies. J Am Coll Cardiol. 2008;52:1250–1260.
[7] Chatzifrangkeskou M, Le Dour C, Wu W, et al. ERK1/
2 directly acts on CTGF/CCN2 expression to mediate
myocardial fibrosis in cardiomyopathy caused by
mutations in the lamin A/C gene. Hum Mol Genet.
2016;25:2220–2233.
[8] Le Dour C, Macquart C, Sera F, et al. Decreased WNT/
beta-catenin signalling contributes to the pathogenesis
of dilated cardiomyopathy caused by mutations in the
lamin a/C gene. Hum Mol Genet. 2017;26:333–343.
[9] Wu W, Chordia MD, Hart BP, et al. Macrocyclic
MEK1/2 inhibitor with efficacy in a mouse model of
cardiomyopathy caused by lamin A/C gene mutation.
Bioorg Med Chem. 2017;25:1004–1013.
[10] Choi JC, Muchir A, Wu W, et al. Temsirolimus acti-
vates autophagy and ameliorates cardiomyopathy
caused by lamin A/C gene mutation. Sci Transl Med.
2012;4:144ra102.
[11] Ramos FJ, Chen SC, Garelick MG, et al. Rapamycin
reverses elevated mTORC1 signaling in lamin A/C-
deficient mice, rescues cardiac and skeletal muscle
function, and extends survival. Sci Transl Med.
2012;4:144ra103.
[12] Mattioli E, Columbaro M, Capanni C, et al. Prelamin
A-mediated recruitment of SUN1 to the nuclear envel-
ope directs nuclear positioning in human muscle. Cell
Death Differ. 2011;18:1305–1315.
[13] Zhou C, Li C, Zhou B, et al. Novel nesprin-1 mutations
associated with dilated cardiomyopathy cause nuclear
envelope disruption and defects in myogenesis. Hum
Mol Genet. 2017;26:2258–2276.
[14] Meinke P, Mattioli E, Haque F, et al. Muscular dystro-
phy-associated SUN1 and SUN2 variants disrupt
nuclear-cytoskeletal connections and myonuclear orga-
nization. PLoS Genetics. 2014;10:e1004605.
[15] Evangelisti C, Bernasconi P, Cavalcante P, et al.
Modulation of TGFbeta 2 levels by lamin A in U2-OS
osteoblast-like cells: understanding the osteolytic pro-
cess triggered by altered lamins. Oncotarget.
2015;6:7424–7437.
[16] Bernasconi P, Carboni N, Ricci G, et al. Elevated TGF β
2 serum levels in Emery-Dreifuss muscular dystrophy:
implications for myocyte and tenocyte differentiation
and fibrogenic processes. Nucleus. 2018 in press
[17] Bertacchini J, Beretti F, Cenni V, et al. The protein kinase
Akt/PKB regulates both prelamin A degradation and
Lmna gene expression. FASEB J. 2013;27:2145–2155.
[18] Roncarati R, Viviani Anselmi C, Krawitz P, et al.
Doubly heterozygous LMNA and TTN mutations
revealed by exome sequencing in a severe form of
dilated cardiomyopathy. EJHG. 2013;21:1105–1111.
[19] Granger B, Gueneau L, Drouin-Garraud V, et al.
Modifier locus of the skeletal muscle involvement in
Emery-Dreifuss muscular dystrophy. Hum Genet.
2011;129:149–159.
456 G. BORIANI ET AL.
[20] Muntoni F, Bonne G, Goldfarb LG, et al. Disease
severity in dominant Emery Dreifuss is increased by
mutations in both emerin and desmin proteins. Brain.
2006;129:1260–1268.
[21] Bonne G, Yaou RB, Beroud C, et al. 108th ENMC
international workshop, 3rd workshop of the MYO-
CLUSTER project: EUROMEN, 7th international
Emery-Dreifuss Muscular Dystrophy (EDMD) work-
shop, 13-15 September 2002, Naarden, The
Netherlands. Neuromuscular Disord. 2003;13:508–515.
[22] Ben Yaou R, Gueneau L, Demay L, et al. Heart invol-
vement in lamin A/C related diseases. Arch Mal Coeur
Vaiss. 2006;99:848–855.
[23] Van Berlo JH, de VoogtWG, van der Kooi AJ, et al. Meta-
analysis of clinical characteristics of 299 carriers of
LMNA gene mutations: do lamin A/Cmutations portend
a high risk of sudden death? J Mol Med. 2005;83:79–83.
[24] Kumar S, Baldinger SH, Gandjbakhch E, et al. Long-
term arrhythmic and nonarrhythmic outcomes of
lamin A/C mutation carriers. J Am Coll Cardiol.
2016;68:2299–2307.
[25] Bertini M, Ziacchi M, Biffi M, et al. Effects of cardiac
resynchronisation therapy on dilated cardiomyopathy
with isolated ventricular non-compaction. Heart.
2011;97:295–300.
[26] Boriani G, Diemberger I, Martignani C, et al. The epide-
miological burden of atrial fibrillation: a challenge for
clinicians and health care systems. Eur Heart J.
2006;27:893–894.
[27] Ollila L, Nikus K, Holmström M, et al. Clinical disease
presentation and ECG characteristics of LMNA muta-
tion carriers. Open Heart. 2017;4:e000474.
[28] Fishbein MC, Siegel RJ, Thompson CE, et al. Sudden
death of a carrier of X-linked Emery-Dreifuss muscular
dystrophy. Ann Intern Med. 1993;119:900–905.
[29] Boriani G, Proietti M. Atrial fibrillation prevention: an
appraisal of current evidence. Heart. 2018;104(11):882–
887.
[30] Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/
APHRS/SOLAECE expert consensus on atrial cardio-
myopathies: definition, characterization, and clinical
implication. Europace. 2016;18:1455–1490.
[31] Kirchhof P, Breithardt G, Bax J, et al. A roadmap to
improve the quality of atrial fibrillation management:
proceedings from the fifth atrial fibrillation network/
European Heart Rhythm Association consensus con-
ference. Europace 2016; 18:37–50.
[32] Boriani G, Cimaglia P, Fantecchi E, et al. Non-valvular
atrial fibrillation: potential clinical implications of the
heterogeneous definitions used in trials on new oral
anticoagulants. J Cardiovasc Med. 2015;16:491–496.
[33] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC
guidelines for the management of atrial fibrillation
developed in collaboration with EACTS. Eur Heart J.
2016;37:2893–2962.
[34] Heidbuchel H, Verhamme P, Alings M, et al. Updated
European Heart Rhythm Association practical guide on
the use of non-vitamin-K antagonist anticoagulants in
patients with non-valvular atrial fibrillation: executive
summary. Eur Heart J. 2017;38:2137–2149.
[35] Steffel J, Verhamme P, Potpara TS, et al. The 2018
European Heart Rhythm Association practical guide
on the use of non-vitamin K antagonist oral anticoa-
gulants in patients with atrial fibrillation: executive
summary. Europace. 2018.
[36] Boriani G, Valzania C, Biffi M, et al. Asymptomatic lone
atrial fibrillation - how can we detect the arrhythmia? Curr
Pharm Des. 2015;21:659–666.
[37] Boriani G, Laroche C, Diemberger I, et al.
Asymptomatic atrial fibrillation: clinical correlates,
management, and outcomes in the EORP-AF pilot
general registry. Am J Med. 2015;128:509–518.e502.
[38] SiontisKC,GershBJ, Killian JM, et al. Typical, atypical, and
asymptomatic presentations of new-onset atrial fibrillation
in the community: characteristics and prognostic implica-
tions. Heart Rhythm. 2016;13:1418–1424.
[39] Freedman B, Camm J, Calkins H, et al. Screening for
atrial fibrillation: a report of the AF-SCREEN interna-
tional collaboration. Circulation 2017; 135:1851–1867.
[40] Mairesse GH, Moran P, Van Gelder IC, et al. Screening
for atrial fibrillation: a European Heart Rhythm
Association (EHRA) consensus document endorsed
by the Heart Rhythm Society (HRS), Asia Pacific
Heart Rhythm Society (APHRS), and Sociedad
Latinoamericana de Estimulacion Cardiaca y
Electrofisiologia (SOLAECE). Europace.
2017;19:1589–1623.
[41] Biffi M, Ziacchi M, Ricci RP, et al. Can we predict new
AF occurrence in single-chamber ICD patients?
Insights from an observational investigation. Int J
Cardiol. 2017;230:275–280.
[42] van Rijsingen IA, Bakker A, Azim D, et al. Lamin A/C
mutation is independently associated with an increased
risk of arterial and venous thromboembolic complica-
tions. Int J Cardiol. 2013;168:472–477.
[43] van Tintelen JP, Hofstra RM, Katerberg H, et al. High
yield of LMNA mutations in patients with dilated
cardiomyopathy and/or conduction disease referred to
cardiogenetics outpatient clinics. Am Heart J.
2007;154:1130–1139.
[44] Sedaghat-Hamedani F, Haas J, Zhu F, et al. Clinical
genetics and outcome of left ventricular non-compac-
tion cardiomyopathy. Eur Heart J. 2017;38:3449–3460.
[45] McNally EM, Mestroni L. Dilated cardiomyopathy:
genetic determinants and mechanisms. Circ Res.
2017;121:731–748.
[46] Fatkin D, MacRae C, Sasaki T, et al. Missense muta-
tions in the rod domain of the lamin A/C gene as
causes of dilated cardiomyopathy and conduction-sys-
tem disease. N Engl J Med. 1999;341:1715–1724.
[47] Bécane HM, Bonne G, Varnous S, et al. High incidence of
sudden death with conduction system and myocardial
disease due to lamins A and C gene mutation. Pacing
Clin Electrophysiol. 2000;23:1661–1666.
NUCLEUS 457
[48] Rapezzi C, Arbustini E, Caforio AL, et al. Diagnostic
work-up in cardiomyopathies: bridging the gap
between clinical phenotypes and final diagnosis. A
position statement from the ESC working group on
myocardial and pericardial diseases. Eur Heart J.
2013;34:1448–1458.
[49] Boriani G, Biffi M, Martignani C, et al. Cardiac resyn-
chronization by pacing: an electrical treatment of heart
failure. Int J Cardiol. 2004;94:151–161.
[50] Boriani G, Berti E, Belotti LM, et al. Cardiac device
therapy in patients with left ventricular dysfunction
and heart failure: ‘real-world’ data on long-term out-
comes (mortality, hospitalizations, days alive and out
of hospital). Eur J Heart Fail. 2016;18:693–702.
[51] Sanna T, Dello Russo A, Toniolo D, et al. Cardiac
features of Emery-Dreifuss muscular dystrophy caused
by lamin A/C gene mutations. Eur Heart J.
2003;24:2227–2236.
[52] Meune C, Van Berlo JH, Anselme F, et al. Primary
prevention of sudden death in patients with lamin A/
C gene mutations. N Engl J Med. 2006;354:209–210.
[53] van Rijsingen IA, Arbustini E, Elliott PM, et al. Risk
factors for malignant ventricular arrhythmias in lamin
a/c mutation carriers a European cohort study. J Am
Coll Cardiol. 2012;59:493–500.
[54] SajM, Dabrowski R, Labib S, et al. Variants of the laminA/
C (LMNA) gene in non-valvular atrial fibrillation patients:
a possible pathogenic role of the Thr528Metmutation.Mol
Diagn Ther. 2012;16:99–107.
[55] Anselme F, Moubarak G, Savouré A, et al. Implantable
cardioverter-defibrillators in lamin A/C mutation car-
riers with cardiac conduction disorders. Heart Rhythm.
2013;10:1492–1498.
[56] Maggi L, D’Amico A, Pini A, et al. LMNA-associated
myopathies: the Italian experience in a large cohort of
patients. Neurology. 2014;83:1634–1644.
[57] Forleo C, Carmosino M, Resta N, et al. Clinical and
functional characterization of a novel mutation in
lamin a/c gene in a multigenerational family with
arrhythmogenic cardiac laminopathy. PLoS One.
2015;10:e0121723.
[58] Steckiewicz R, Stolarz P, Świętoń E, et al. Cardiac
pacing in 21 patients with Emery-Dreifuss muscular
dystrophy: a single-centre study with a 39-year fol-
low-up. Kardiol Pol. 2016;74:576–583.
[59] Olde Nordkamp LR, Postema PG, Knops RE, et al.
Implantable cardioverter-defibrillator harm in young
patients with inherited arrhythmia syndromes: A systema-
tic review and meta-analysis of inappropriate shocks and
complications. Heart Rhythm. 2016;13:443–454.
[60] Kumar S, Androulakis AF, Sellal JM, et al. Multicenter
experience with catheter ablation for ventricular tachy-
cardia in lamin A/C cardiomyopathy. Circ Arrhythm
Electrophysiol. 2016;9:e004357.
[61] Hasselberg NE, Haland TF, Saberniak J, et al. Lamin A/
C cardiomyopathy: young onset, high penetrance, and
frequent need for heart transplantation. Eur Heart J.
2018;39:853–860.
[62] Nishiuchi S, Makiyama T, Aiba T, et al. Gene-based
risk stratification for cardiac disorders in LMNA muta-
tion carriers. Circ Cardiovasc Genet. 2017;10(6). pii:
e001603. doi:10.1161/CIRCGENETICS.116.001603.
[63] Boriani G, Diemberger I, Martignani C, et al.
Telecardiology and remote monitoring of implanted elec-
trical devices: the potential for fresh clinical care perspec-
tives. J Gen Intern Med. 2008;23(Suppl 1):73–77.
[64] Landolina M, Perego GB, Lunati M, et al. Remote
monitoring reduces healthcare use and improves qual-
ity of care in heart failure patients with implantable
defibrillators: the evolution of management strategies
of heart failure patients with implantable defibrillators
(EVOLVO) study. Circulation. 2012;125:2985–2992.
[65] Varma N, Epstein AE, Irimpen A, et al. Efficacy and
safety of automatic remote monitoring for implantable
cardioverter-defibrillator follow-up: the Lumos-T
Safely Reduces Routine Office Device Follow-up
(TRUST) trial. Circulation. 2010;122:325–332.
[66] Boriani G, Da Costa A, Ricci RP, et al. The MOnitoring
Resynchronization dEvices and CARdiac patiEnts
(MORE-CARE) randomized controlled trial: phase 1
results on dynamics of early intervention with remote
monitoring. J Med Internet Res. 2013;15:e167.
[67] Hindricks G, Taborsky M, Glikson M, et al. Implant-
based multiparameter telemonitoring of patients with
heart failure (IN-TIME): a randomised controlled trial.
Lancet. 2014;384:583–590.
[68] Boriani G, Braunschweig F, Deharo JC, et al. Impact of
extending device longevity on the long-term costs of
implantable cardioverter-defibrillator therapy: a mod-
elling study with a 15-year time horizon. Europace.
2013;15:1453–1462.
[69] Boriani G, Merino J, Wright D, et al. Battery longevity
of implantable cardioverter-defibrillators and cardiac
resynchronization therapy defibrillators: technical,
clinical and economic aspects: an expert review paper
from EHRA. Europace. 2018 May 10; [Epub ahead of
print]. DOI:10.1093/europace/euy066
[70] Udo EO, Zuithoff NP, van Hemel NM, et al. Incidence
and predictors of short- and long-term complications
in pacemaker therapy: the FOLLOWPACE study.
Heart Rhythm. 2012;9:728–735.
[71] Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications
after cardiac implantable electronic device implantations:
an analysis of a complete, nationwide cohort in Denmark.
Eur Heart J. 2014;35:1186–1194.
[72] Reynolds D, Duray GZ, Omar R, et al. A leadless
intracardiac transcatheter pacing system. N Engl J
Med. 2016;374:533–541.
[73] Duray GZ, Ritter P, El-Chami M, et al. Long-term
performance of a transcatheter pacing system: 12-
month results from the micra transcatheter pacing
study. Heart Rhythm. 2017;14:702–709.
458 G. BORIANI ET AL.
[74] Roberts PR, Clementy N, Al Samadi F, et al. A leadless
pacemaker in the real-world setting: the Micra
Transcatheter Pacing System Post-Approval Registry.
Heart Rhythm. 2017;14:1375–1379.
[75] Grubman E, Ritter P, Ellis CR, et al. To retrieve, or not
to retrieve: system revisions with the micra transcath-
eter pacemaker. Heart Rhythm. 2017;14:1801–1806.
[76] Brouwer TF, Yilmaz D, Lindeboom R, et al. Long-term
clinical outcomes of subcutaneous versus transvenous
implantable defibrillator therapy. J Am Coll Cardiol.
2016;68:2047–2055.
[77] Basu-Ray I, Liu J, Jia X, et al. Subcutaneous versus
transvenous implantable defibrillator therapy. JACC:
Clin Electrophysiol. 2017;3:1475–1483.
[78] Boriani G, Ziacchi M, Nesti M, et al. Cardiac resyn-
chronization therapy: how did consensus guidelines
from Europe and the United States evolve in the last
15 years? Int J Cardiol. 2018;261:119–129.
NUCLEUS 459
